Physician profile
Yashpal Modi
NPI 1164782991
$13,208.72
in general payments reported to CMS, 2019-2025
65 companies · $1,440 in 2025
The $1,440 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,174 · 2020: $1,304 · 2021: $2,562 · 2022: $2,396 · 2023: $2,158 · 2024: $1,175 · 2025: $1,440.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,705 · Education: $67.16.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,705.41 |
| Education | $67.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $1,222.73 | 2019-2025 | Opdivo, Opdualag, Augtyro |
| Merck Sharp & Dohme LLC | $1,132.67 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Pfizer INC. | $1,035.41 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $927.32 | 2019-2025 | |
| Amgen INC. | $794.71 | 2019-2023 | Lumakras, Evenity, Prolia |
| Astrazeneca Pharmaceuticals LP | $773.65 | 2019-2025 | Lynparza, Tagrisso, Enhertu |
| Janssen Biotech, INC. | $658.16 | 2019-2025 | Carvykti, Erleada, Imbruvica |
| Seagen INC. | $649.94 | 2019-2023 | Padcev, Tukysa, Adcetris |
| Celgene Corporation | $462.46 | 2020-2025 | Reblozyl |
| Takeda Pharmaceuticals U.S.A., INC. | $419.64 | 2019-2025 | Iclusig, Alunbrig, Ninlaro |
| Daiichi Sankyo INC. | $375.40 | 2019-2025 | Enhertu, Injectafer, Datroway |
| Pharmacyclics LLC, An Abbvie Company | $367.47 | 2019-2023 | Imbruvica |
| Incyte Corporation | $310.19 | 2019-2025 | Jakafi |
| Genentech USA, INC. | $266.65 | 2019-2024 | Tecentriq, Phesgo, Polivy |
| Astellas Pharma US INC | $254.97 | 2019-2025 | Xtandi, Vyloy, Xospata |
Show all 65 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yashpal Modi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.